Refine by MP, party, committee, province, or result type.
Health committee No, I don't have all of those, but I certainly could provide you with a link to the website.
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee They work very closely as well with patient groups and consumer groups to ensure that the information is spread widely as well.
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee Yes, I'd love to speak to this as well. There's a new field within the type of work we do, and it's being referred to globally as disinvestment in health technologies. That's exactly what he was speaking to here. There are so many things we do in the health care system that were
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee If I may, in speaking to that first question, and probably a little to the second question, Dr. Beaudet mentioned earlier about personalized medicine and the work they're doing with Genome Canada. A great innovation is that they've started to recognize that it's not just about pr
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee I would echo a lot of those comments as well. One of our priorities is in mental health. We do a fair bit of work and review not just of drugs but of newer types of therapy, such as psychological therapies and other social therapies that are helping to both prevent and treat ment
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee It's certainly something we look at when we're doing an assessment of a new technology or an existing technology, just to ensure that those human factors he talked about are actually going to make that technology useful to the system. You have hit on a significant issue, which is
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee Madam Chair, there are probably two things I'd like to say about that. One would be related to the common drug review again. When it was established, every province and the federal programs that deliver health care had their own systems in place. Over the 10 years or so that the
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee It's probably a better question for our colleagues from Quebec. They have their own agency, Institut national d'excellence en services sociaux. It does very similar work to what we do. We do have a memorandum of understanding in place with that organization as well, so we do some
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee All provinces still have their own decision-making. We're not the decision-making body. We provide the recommendations to them, but we have taken away the need for them to have this major review done.
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee Perhaps I could speak to the second question regarding accessibility and the cross-border issues in Canada. Our common drug review, for example, was a program that was set up by the provinces and territories and the drug programs within the federal government. They created it ab
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee It's very different on the technology side. Drugs are so much easier because it's very top-down in most provinces. They have a drug plan and people in the ministry who do have controls in place. Devices are very bottom-up. New devices and new technologies are introduced into the
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee We'll work very closely with the clerk and see what we can produce.
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee Thank you, Madam Chair, and thank you for inviting me to appear before the committee. Let me begin by telling you a bit about the Canadian Agency for Drugs and Technologies in Health, or CADTH. We are an independent, not-for-profit corporation that was established in 1989. We re
October 18th, 2012Committee meeting
Dr. Brian O'Rourke
Health committee It would be very challenging for Health Canada to introduce that type of policy, which is very locally based, to determine the critical drugs that we require in our specific hospital and our specific situation. For many of the decisions it is very important to have the patient-ph
April 3rd, 2012Committee meeting
Dr. Brian O'Rourke
Health committee I think that's an extremely important concept. Sole-sourcing is probably one of the key factors associated with the Sandoz shortage, whether it was the provinces themselves or the group purchasing among all of the hospital groups across the country that led to it. I will refer t
April 3rd, 2012Committee meeting
Dr. Brian O'Rourke